jueves, 12 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

2025: The year the Big 3 backed away from EVs

View original at finance.yahoo.com
2025: The year the Big 3 backed away from EVs The last couple of weeks of the year are typically a slow time in the auto business, at least on the corporate front…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We can't allocate money for things that will not make money. As much as I love those products, the customers in the US were not going to pay for them. And that was the end of that.

    80% confidence
  • The execution at GM has been way more consistent, which is the reason why their margins have been so much larger compared to Ford over the past seven, eight years. I think GM has been [more consistent in execution] under Mary Barra. We've seen as the tables turn, more decisive steps, more control over all the things that the industry throws at them, whether it's supply chain shocks from bottlenecks that emerge, labor union negotiations, you name it.

    80% confidence
  • I wouldn't be surprised if more charges were to happen, and that's only because after Q3 when they put out the $1.6 billion charge announcement, there was a pretty clear statement in their filing which said there could be more material announcements related to program cancelations, supplier charges, etc., very similar to what Ford announced

    80% confidence
  • We're going to do the right hybrids that we think are important for our portfolio, but I also think we have a very strong EV portfolio and a very strong internal combustion [portfolio]. We're going to be positioned to compete well, but also be good stewards of our owners' capital and how we deploy R&D dollars.

    80% confidence
  • Stellantis has launched new ICE product in the US to capitalize on the trend of prolonged combustion engine life and should benefit from a mix skew to ICE particularly in the US

    80% confidence
  • There's no question that the demand environment is going to be challenging. Companies generally expect EV adoption to hit about 5% to 7% of new vehicle sales over the very near term. But our message over the next couple of years is don't sleep on the US EV market.

    80% confidence
  • Ford could conceivably be vulnerable to any upside from EV demand, should it arise

    80% confidence
  • After over-investing in luxury EVs and electric trucks, automakers are now pivoting toward the sub-$35,000 segment, think revamped Bolts and Leafs, to keep EV adoption alive

    80% confidence
  • Overall, ICE technology will be around for longer which is positive for mix of OEMs but at the same time requires additional investments to keep the technology up to date and has caused write-offs on EV model lines. We find that others like GM and Ford are increasingly promoting the narrative around flexible manufacturing.

    80% confidence
  • We view it as a decisive, strategic reset. Historically, Ford's been a little slow to act on very important strategic items in terms of cutting losses early

    80% confidence
  • We think that for Stellantis to get back towards levels of profitability we see at GM, it's going to take a while

    80% confidence
  • It does give them long-term flexibility and near term we see the path towards less losses, because they're going to be having less underutilized EV assets

    80% confidence
  • They still have a wide portfolio and enough capacity to adjust to market demand, and they'll have, of course, new technologies as well

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,565 documentos fuente archivados
Consulta estos datos → isubstrate.com
2025: The year the Big 3 backed away from EVs — Source | Via News | es.VIA.NEWS